Open AccessDiallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK / SIRT1 / PGC1α pathway
Author(s) -
Wang Zhaojun,
Yan Yi,
Lou Yijie,
Huang Xiaoyan,
Liu Lijian,
Weng Zhuofan,
Cui Yusheng,
Wu Xinyue,
Cai Huijun,
Chen Xiaohui,
Ji Yunxi
Publication year - 2023
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.15627
Subject(s) - diallyl trisulfide , ampk , cisplatin , ovarian cancer , cancer research , in vivo , apoptosis , signal transduction , cancer cell , chemistry , pharmacology , cancer , chemotherapy , phosphorylation , biology , biochemistry , medicine , protein kinase a , microbiology and biotechnology
Platinum‐based chemotherapy promotes drug resistance in ovarian cancer. We investigated the antichemoresistance characteristics of diallyl trisulfide (DATS) in cisplatin‐resistant ovarian cancer cells, in vitro and in vivo. Previous preclinical studies have revealed that DATS regulates distinct hallmark cancer‐signaling pathways. The cell cycle pathway is the most investigated signaling pathway in DATS. Additionally, post‐DATS treatment has been found to promote proapoptotic capacity through the regulation of intrinsic and extrinsic apoptotic pathway components. In the present study, we found that treating cisplatin‐sensitive and cisplatin‐resistant ovarian cell lines with DATS inhibited their proliferation and reduced their IC 50. It induced cell apoptosis and promoted oxidative phosphorylation through the regulation of the AMPK/SIRT1/PGC1α pathway, OXPHOS, and enhanced chemotherapy sensitivity. DATS treatment alleviated glutamine consumption in cisplatin‐resistant cells. Our findings highlight the role of DATS in overcoming drug resistance in ovarian cancer in vitro and in vivo. In addition, we elucidated the role of the AMPK/SIRT1/PGC1α signaling pathway as a potential target for the treatment of drug‐resistant ovarian cancer.